Israeli tech enhances immunotherapy response prediction.
Researchers at Ben-Gurion University of the Negev have developed a new bio-sensing technology that predicts cancer patients’ response to immune checkpoint inhibitor (ICI) immunotherapy. The new Immuno-checkpoint Artificial Reporter (IcAR) technology has been licensed to OncoHost, an Israeli-guided oncology company, which will seek US Food and Drug Administration approval. The technology has the potential to improve the effectiveness of immunotherapy and spare patients toxicity and debilitating side effects.